Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KRISTI HAWLEY

Allopathic & Osteopathic Physicians Dermatology

NPI
1821350745
CMS profile
1287903
Location
CALEDONIA, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$201,183.38

402 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 7 of 9; records 301–350 of 402 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KRISTI HAWLEY

NPI 1821350745 · CMS profile ID 1287903

Allopathic & Osteopathic Physicians / Dermatology

CALEDONIA, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 7 of 9; records 301–350 of 402 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821350745?year=2021&recipient=provider&page=7#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KRISTI HAWLEY, NPI 1821350745, CMS profile ID 1287903. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 9; records 301–350 of 402 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821350745?year=2021&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). KRISTI HAWLEY, NPI 1821350745, CMS profile ID 1287903. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 9; records 301–350 of 402 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821350745?year=2021&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
KRISTI HAWLEY, NPI 1821350745, CMS profile ID 1287903, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 9; records 301–350 of 402 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1821350745?year=2021&recipient=provider&page=7#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

402 matching records · $201,183.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 402 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 301–350 of 402.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $16.6904/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812713503 CMS
UCB, Inc. $24.9104/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807336775 CMS
UCB, Inc. $103.9404/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807340313 CMS
VYNE Pharmaceuticals Inc. $12.8704/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830832675 CMS
AbbVie Inc. $1,875.0004/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794777699 CMS
AbbVie Inc. $23.9704/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794777697 CMS
Amgen Inc. $18.2904/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825530541 CMS
AbbVie Inc. $5.0204/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794777693 CMS
Galderma Laboratories, L.P. $8.4804/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855279165 CMS
Galderma Laboratories, L.P. $12.0004/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855279167 CMS
AbbVie Inc. $3.3504/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794777689 CMS
Janssen Biotech, Inc. $3.3604/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788721077 CMS
UCB, Inc. $4.4904/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807325165 CMS
Amgen Inc. $2,000.0004/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826378131 CMS
UCB, Inc. $1,600.0003/31/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807325727 CMS
UCB, Inc. $1,600.0003/31/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807372513 CMS
AbbVie Inc. $1,875.0003/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794777685 CMS
Janssen Biotech, Inc. $1,437.5003/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788721025 CMS
Almirall LLC $12.6103/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819689235 CMS
UCB, Inc. $1,600.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807299859 CMS
UCB, Inc. $1,600.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807325679 CMS
UCB, Inc. $1,600.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807326003 CMS
Janssen Biotech, Inc. $2.3603/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788721061 CMS
VYNE Pharmaceuticals Inc. $28.5903/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830817857 CMS
GENZYME CORPORATION $22.0503/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843649861 CMS
UCB, Inc. $1,600.0003/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807329023 CMS
UCB, Inc. $1,600.0003/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807469033 CMS
UCB, Inc. $1,600.0003/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807469035 CMS
Novartis Pharmaceuticals Corporation $19.3303/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812713501 CMS
UCB, Inc. $15.3503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807329659 CMS
AbbVie Inc. $26.0703/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794777681 CMS
Amgen Inc. $21.3203/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825530535 CMS
Lilly USA, LLC $13.2903/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818621715 CMS
Janssen Biotech, Inc. $1.4803/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788721033 CMS
Galderma Laboratories, L.P. $11.9503/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855279163 CMS
Genentech USA, Inc. $16.9103/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835938211 CMS
Myriad Genetic Laboratories, Inc. $15.6903/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834576839 CMS
Novartis Pharmaceuticals Corporation $9.9403/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812713499 CMS
UCB, Inc. $1,600.0003/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807319447 CMS
UCB, Inc. $1,600.0003/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807328975 CMS
AbbVie Inc. $12.9103/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794777677 CMS
PFIZER INC. $19.1403/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832804461 CMS
Regeneron Healthcare Solutions, Inc. $5.4603/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809585563 CMS
AbbVie Inc. $23.8703/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794777673 CMS
GENZYME CORPORATION $74.5003/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843649885 CMS
Janssen Biotech, Inc. $20.1402/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788721031 CMS
AbbVie Inc. $9.7502/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794777669 CMS
Journey Medical Corporation $17.7202/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852082085 CMS
UCB, Inc. $1,600.0002/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807295049 CMS
UCB, Inc. $1,600.0002/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807303305 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $347,829.97 532
PY2020 $201,912.82 336
PY2021 $201,183.38 402
PY2022 $287,503.69 470
PY2023 $393,381.07 584
PY2024 $418,907.32 595
PY2025 $344,377.99 508

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $25,577.10 5
PY2025 Principal investigator $242,985.47 35
PY2024 Recipient $11,332.86 2
PY2024 Principal investigator $57,364.76 14
PY2023 Recipient $9,676.43 4
PY2023 Principal investigator $7,833.43 5
PY2022 Recipient $653.00 1
PY2022 Principal investigator $157.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $5,500.00 12/25/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN PLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418003
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,278.85 12/18/2025 Non-covered Recipient Entity
Derm Institute of West Michigan PLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431356
Principal investigator 1 ABBVIE INC. $4,124.00 12/04/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527352
Recipient SANOFI US SERVICES INC. $5,206.50 12/04/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226125646
Principal investigator 1 SANOFI US SERVICES INC. $4,085.00 11/19/2025 Non-covered Recipient Entity
The Derm Institute Of West Michigan Plc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226099359
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,103.35 11/13/2025 Non-covered Recipient Entity
Derm Institute of West Michigan PLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431354
Principal investigator 1 Novartis Pharmaceuticals Corporation $523.78 11/10/2025 Non-covered Recipient Entity
THE DERM INSTITUTE OF WEST MICHIGAN, PLC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190310366
Principal investigator 1 SANOFI US SERVICES INC. $195.00 11/07/2025 Non-covered Recipient Entity
The Derm Institute Of West Michigan Plc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226099353
Principal investigator 1 Janssen Research & Development, LLC $2,288.00 10/27/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN PLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418019
Principal investigator 1 Janssen Research & Development, LLC $1,960.00 10/24/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN PLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175417982
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $15,189.53 10/23/2025 Non-covered Recipient Entity
Derm Institute of West Michigan PLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431352
Principal investigator 1 ABBVIE INC. $12,726.24 10/09/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202515315
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,599.45 10/09/2025 Non-covered Recipient Entity
Derm Institute of West Michigan PLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431350
Recipient SANOFI US SERVICES INC. $3,951.00 10/08/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226125641
Principal investigator 1 Janssen Research & Development, LLC $1,960.00 09/29/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN PLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418009
Recipient SANOFI US SERVICES INC. $2,048.40 09/17/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226125637
Principal investigator 1 SANOFI US SERVICES INC. $195.00 09/10/2025 Non-covered Recipient Entity
The Derm Institute Of West Michigan Plc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226099247
Principal investigator 1 Janssen Research & Development, LLC $4,716.00 09/08/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN PLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418026
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,004.83 08/13/2025 Non-covered Recipient Entity
Derm Institute of West Michigan PLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431348
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $13,177.36 08/12/2025 Non-covered Recipient Entity
Derm Institute of West Michigan PLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431346
Principal investigator 1 Janssen Research & Development, LLC $6,393.00 07/31/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN PLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175417992
Principal investigator 1 Janssen Research & Development, LLC $2,779.00 07/28/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN PLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418031
Recipient SANOFI US SERVICES INC. $2,664.00 07/23/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226125653
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 07/11/2025 Non-covered Recipient Entity
The Derm Institute Of West Michigan Plc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226099239
Principal investigator 1 SANOFI US SERVICES INC. $3,415.00 07/11/2025 Non-covered Recipient Entity
The Derm Institute Of West Michigan Plc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226099276
Principal investigator 1 ABBVIE INC. $10,573.00 07/02/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202496347
Recipient SANOFI US SERVICES INC. $11,707.20 06/27/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226125650
Principal investigator 1 Janssen Research & Development, LLC $1,737.00 05/26/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN PLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175417998
Principal investigator 1 SANOFI US SERVICES INC. $390.00 05/21/2025 Non-covered Recipient Entity
The Derm Institute Of West Michigan Plc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226099202
Principal investigator 1 Eli Lilly and Company $15,526.00 05/13/2025 Non-covered Recipient Entity
THE DERM INSTITUTE OF WEST MICHIGAN
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187891208
Principal investigator 1 Eli Lilly and Company $31,290.00 05/07/2025 Non-covered Recipient Entity
THE DERM INSTITUTE OF WEST MICHIGAN
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187892150
Principal investigator 1 Eli Lilly and Company $5,000.00 04/11/2025 Non-covered Recipient Entity
THE DERM INSTITUTE OF WEST MICHIGAN
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1187890830
Principal investigator 1 SANOFI US SERVICES INC. $2,561.25 04/11/2025 Non-covered Recipient Entity
The Derm Institute Of West Michigan Plc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226099209
Principal investigator 1 Janssen Research & Development, LLC $2,460.00 03/24/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN PLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418015
Principal investigator 1 Janssen Research & Development, LLC $1,728.00 03/03/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN PLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175417986
Principal investigator 1 SANOFI US SERVICES INC. $1,178.75 02/19/2025 Non-covered Recipient Entity
The Derm Institute Of West Michigan Plc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226099061
Principal investigator 1 Eli Lilly and Company $50,454.00 01/28/2025 Non-covered Recipient Entity
THE DERM INSTITUTE OF WEST MICHIGAN
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187891206
Principal investigator 1 Eli Lilly and Company $2,790.08 01/27/2025 Non-covered Recipient Entity
THE DERM INSTITUTE OF WEST MICHIGAN
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187890564
Principal investigator 1 Janssen Research & Development, LLC $4,624.00 01/27/2025 Non-covered Recipient Entity
DERM INSTITUTE OF WEST MICHIGAN PLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175418037
Principal investigator 1 SANOFI US SERVICES INC. $7,460.00 01/15/2025 Non-covered Recipient Entity
The Derm Institute Of West Michigan Plc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226099056